```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 01   New pricing for the Save Answers for SciFinder Wizard within
                   STN Express with Discover!
 NEWS  4  OCT 28   KOREAPAT now available on STN
 NEWS  5  NOV 30   PHAR reloaded with additional data
 NEWS  6  DEC 01   LISA now available on STN
 NEWS  7  DEC 09   12 databases to be removed from STN on December 31, 2004
 NEWS  8  DEC 15   MEDLINE update schedule for December 2004
 NEWS  9  DEC 17   ELCOM reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  10 DEC 17   COMPUAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  11 DEC 17   SOLIDSTATE reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  12 DEC 17   CERAB reloaded; updating to resume; current-awareness
                   alerts (SDIs) affected
 NEWS  13 DEC 17   THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
 NEWS  14 DEC 30   EPFULL: New patent full text database to be available on STN
 NEWS  15 DEC 30   CAPLUS - PATENT COVERAGE EXPANDED
 NEWS  16 JAN 03   No connect-hour charges in EPFULL during January and
                   February 2005

 NEWS EXPRESS  OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:13:32 ON 05 JAN 2005

=> file medline, biosis, biotechds, embase, wpids, fsta, dgene, japio, uspatful,
jicst, wpix, scisearch
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

```
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.21        0.21

FILE 'MEDLINE' ENTERED AT 19:14:05 ON 05 JAN 2005

FILE 'BIOSIS' ENTERED AT 19:14:05 ON 05 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

FILE 'BIOTECHDS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'EMBASE' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'FSTA' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 International Food Information Service

FILE 'DGENE' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'JAPIO' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Japanese Patent Office (JPO)- JAPIO

FILE 'USPATFULL' ENTERED AT 19:14:05 ON 05 JAN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JICST-EPLUS' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 Japan Science and Technology Agency (JST)

FILE 'WPIX' ENTERED AT 19:14:05 ON 05 JAN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 19:14:05 ON 05 JAN 2005
Copyright (c) 2005 The Thomson Corporation.

=> s (p53) and (ATM or atacia-telangiectasia mutated?)
L1        2748 (P53) AND (ATM OR ATACIA-TELANGIECTASIA MUTATED?)

=> s ATM or Ataxia-telangiectasia mutated?
L2      170895 ATM OR ATAXIA-TELANGIECTASIA MUTATED?

=> s (p53)
L3      205530 (P53)

=> s l3 and l2
L4        2824 L3 AND L2

=> s l4 an l1
MISSING OPERATOR L4 AN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l4 and l1
L5        2748 L4 AND L1

=> s l5 and binding
L6         842 L5 AND BINDING

=> s (P53) and (binding) and (ATM)
L7         842 (P53) AND (BINDING) AND (ATM)
```

```
=> s (p53) and (binding) and (ATR)
L8          218 (P53) AND (BINDING) AND (ATR)

=> s l8 and l7
L9          177 L8 AND L7

=> s phosphorylation and l9
L10         122 PHOSPHORYLATION AND L9

=> e Meyn /au
E1            3     MEYMERIT J C/AU
E2            2     MEYMOUNA M/AU
E3            1 --> MEYN/AU
E4            7     MEYN A/AU
E5            2     MEYN A W/AU
E6            1     MEYN ADIER J/AU
E7            1     MEYN ASHLEIGH W/AU
E8            3     MEYN B/AU
E9           51     MEYN C/AU
E10           2     MEYN C K/AU
E11           1     MEYN CATHERINE K/AU
E12          18     MEYN CORNELIS/AU

=> s e5
L11           2 "MEYN A W"/AU

=> d l11 ti abs ibib tot

L11  ANSWER 1 OF 2  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
TI   The Extraction and Infrared Identification of Gamma-Hydroxybutyric Acid
     (GHB) from Aqueous Solutions.
AB   The chemical analysis of gamma-hydroxybutyric acid (GHB) in most forensic
     laboratories is complicated by the highly polar nature of the GHB
     molecule, which makes it unsuitable for direct analysis by gas
     chromatography (GC). Consequently, a popular analytical approach is to
     convert GHB into the corresponding lactone or a derivative compound that
     is then identified by mass spectrometry employed in conjunction with GC
     (GC/MS). An alternative approach is presented here where GHB may be
     isolated as a free acid specie from complex aqueous solutions employing a
     liquid-liquid extraction technique. This approach can yield a relatively
     pure residue of GHB that presents an infrared transmission spectrum that
     is sufficiently distinct for identification purposes. Infrared
     spectroscopy (IR) is a very popular technique that is available to most
     crime laboratories. The liquid-liquid extraction behavior of GHB is
     examined in detail and the uniqueness of the infrared spectrum is
     discussed.
ACCESSION NUMBER:   2004023417  EMBASE
TITLE:              The Extraction and Infrared Identification of
                    Gamma-Hydroxybutyric Acid (GHB) from Aqueous Solutions.
AUTHOR:             Chappell J.S.; Meyn A.W.; Ngim K.K.
CORPORATE SOURCE:   Dr. J.S. Chappell, Drug Enforcement Administration, Western
                    Laboratory, 390 Main Street, San Francisco, CA 94105,
                    United States
SOURCE:             Journal of Forensic Sciences, (2004) 49/1 (52-59).
                    Refs: 25
                    ISSN: 0022-1198  CODEN: JFSCAS
COUNTRY:            United States
DOCUMENT TYPE:      Journal; Article
FILE SEGMENT:       029     Clinical Biochemistry
                    049     Forensic Science Abstracts
LANGUAGE:           English
SUMMARY LANGUAGE:   English
```

L11 ANSWER 2 OF 2 SCISEARCH COPYRIGHT (c) 2005 The Thomson Corporation. on STN

TI The extraction and infrared identification of Gamma-hydroxybutyric acid (GHB) from aqueous solutions

AB The chemical analysis of gamma-hydroxybutyric acid (GHB) in most forensic laboratories is complicated by the highly polar nature of the GHB molecule, which makes it unsuitable for direct analysis by gas chromatography (GC). Consequently, a popular analytical approach is to convert GHB into the corresponding lactoné or a derivative compound that is then identified by mass spectrometry employed in conjunction with GC (GC/MS). An alternative approach is presented here where GHB may be isolated as a free acid specie from complex aqueous solutions employing a liquid-liquid extraction technique. This approach can yield a relatively pure residue of GHB that presents an infrared transmission spectrum that is sufficiently distinct for identification purposes. Infrared spectroscopy (IR) is a very popular technique that is available to most crime laboratories. The liquid-liquid extraction behavior of GHB is examined in detail and the uniqueness of the infrared spectrum is discussed.

ACCESSION NUMBER: 2004:80679 SCISEARCH
THE GENUINE ARTICLE: 762DV
TITLE: The extraction and infrared identification of Gamma-hydroxybutyric acid (GHB) from aqueous solutions
AUTHOR: Chappell J S (Reprint); **Meyn A W**; Ngim K K
CORPORATE SOURCE: Drug Enforcement Adm, Western Lab, 390 Main St, Room 700, San Francisco, CA 94105 USA (Reprint); Drug Enforcement Adm, Western Lab, San Francisco, CA 94105 USA
COUNTRY OF AUTHOR: USA
SOURCE: JOURNAL OF FORENSIC SCIENCES, (JAN 2004) Vol. 49, No. 1, pp. 52-59.
Publisher: AMER SOC TESTING MATERIALS, 100 BARR HARBOR DR, W CONSHOHOCKEN, PA 19428-2959 USA.
ISSN: 0022-1198.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 24
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

=> d his

(FILE 'HOME' ENTERED AT 19:13:32 ON 05 JAN 2005)

FILE 'MEDLINE, BIOSIS, BIOTECHDS, EMBASE, WPIDS, FSTA, DGENE, JAPIO, USPATFULL, JICST-EPLUS, WPIX, SCISEARCH' ENTERED AT 19:14:05 ON 05 JAN 2005

L1 2748 S (P53) AND (ATM OR ATACIA-TELANGIECTASIA MUTATED?)
L2 170895 S ATM OR ATAXIA-TELANGIECTASIA MUTATED?
L3 205530 S (P53)
L4 2824 S L3 AND L2
L5 2748 S L4 AND L1
L6 842 S L5 AND BINDING
L7 842 S (P53) AND (BINDING) AND (ATM)
L8 218 S (P53) AND (BINDING) AND (ATR)
L9 177 S L8 AND L7
L10 122 S PHOSPHORYLATION AND L9
E MEYN /AU
L11 2 S E5

=> s l8 and phosphorylation
L12 156 L8 AND PHOSPHORYLATION

=> s l12 and screening method
7 FILES SEARCHED...

L13 19 L12 AND SCREENING METHOD

=> s l10 and screening method
8 FILES SEARCHED...
L14 12 L10 AND SCREENING METHOD

=> d l13 ti abs ibib tot

L13 ANSWER 1 OF 19 USPATFULL on STN
TI Stress-responsive activator of p300 (strap) protein
AB The invention provides a protein which is a stress-responsive activator of the p300 protein, and nucleic acid sequences encoding the protein. The protein performs a key role in facilitating stress-responsive protein-protein interactions within the p300 co-activator complex. The STRAP protein facilitates the interaction of other proteins in the p300 complex, and is thus a target for assays for modulators of the complex.

ACCESSION NUMBER:	2004:328237 USPATFULL		
TITLE:	Stress-responsive activator of p300 (strap) protein		
INVENTOR(S):	La Thangue, Nicholas Barnie, Strathclyde, UNITED KINGDOM Demonacos, Constantinos, Strathclyde, UNITED KINGDOM Krstic-Demonacos, Marija, Strathclyde, UNITED KINGDOM		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004260062	A1	20041223	
APPLICATION INFO.:	US 2004-471573	A1	20040816	(10)
	WO 2002-GB1349		20020319	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-6782	20010319

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714
NUMBER OF CLAIMS:	24
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	17 Drawing Page(s)
LINE COUNT:	2276

L13 ANSWER 2 OF 19 USPATFULL on STN
TI **P53**-dependent apoptosis-inducing protein and method of screening for apoptosis regulator
AB **p53**-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a **p53**-induced nuclear protein that induces **p53**-dependent apoptosis by regulating **p53** function through Ser 46 **phosphorylation**. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with **p53**-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating **p53**-mediated apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2004:320942 USPATFULL		
TITLE:	**P53**-dependent apoptosis-inducing protein and method of screening for apoptosis regulator		
INVENTOR(S):	Nakamura, Yusuke, Kanagawa, JAPAN Arakawa, Hirofumi, Tokyo, JAPAN		

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2004253595 A1 20041216
APPLICATION INFO.: US 2004-484157 A1 20040726 (10)
WO 2002-JP7305 20020718

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-220349	20010719

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kevin Bastian, Townsend and Townsend and Crew, Two Embarcadero Center, Eighth Floor, San Francisco, CA, 94111-3834
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 19 USPATFULL on STN
TI Modulators of telomere stability
AB The present invention embodies methods of modulating telomere repeat-**binding** factor-2 (TRF2) or cell cycle checkpoint kinase 2 (Chk2) to enhance the survival of a cell. More particularly, the modulators can be used to treat cardiovascular disease by improving the growth and survival of cardiomyocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:307785 USPATFULL
TITLE: Modulators of telomere stability
INVENTOR(S): Schneider, Michael D., Houston, TX, UNITED STATES
Oh, Hidemasa, Houston, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004242461	A1	20041202
APPLICATION INFO.:	US 2004-820583	A1	20040408 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-461095P	20030408 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 4939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 19 USPATFULL on STN
TI Novel SMG-1
AB A novel polypeptide and a novel polynucleotide encoding the same are disclosed.

The polypeptide is SMG-1, a protein included in the phosphatidyl inositol kinase related kinase family, and is useful in constructing a screening system for agents of treating and/or preventing a disease caused by a premature translation termination codon generated by a nonsense mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:178425 USPATFULL
TITLE: Novel SMG-1

INVENTOR(S): Ohno, Shigeo, Tokyo, JAPAN
PATENT ASSIGNEE(S): Japan Science and Technology Agency, Saitama, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004137592	A1	20040715
APPLICATION INFO.:	US 2003-720460	A1	20031124 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-JP10234, filed on 22 Nov 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-156088	20010524

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 3702
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 5 OF 19 USPATFULL on STN
TI Modulation of checkpoint kinase 1 expression
AB Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:127462 USPATFULL
TITLE: Modulation of checkpoint kinase 1 expression
INVENTOR(S): Gaarde, William, Carlsbad, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Watt, Andrew T., Vista, CA, UNITED STATES
PATENT ASSIGNEE(S): Isis Pharmaceuticals Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097446	A1	20040520
APPLICATION INFO.:	US 2002-298994	A1	20021116 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 3681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 6 OF 19 USPATFULL on STN
TI Novel proteases
AB The present invention relates to protease polypeptides, nucleotide sequences encoding the protease polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protease-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:82657 USPATFULL
TITLE: Novel proteases
INVENTOR(S): Plowman, Gregory D., San Carlos, CA, UNITED STATES
Whyte, David, Belmont, CA, UNITED STATES
Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES
Manning, Gerard, Menlo Park, CA, UNITED STATES
Caenepeel, Sean R., Oakland, CA, UNITED STATES
Payne, Vilia A., Chesterfield, MO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004063107	A1	20040401	
APPLICATION INFO.:	US 2003-275107	A1	20030320	(10)
	WO 2001-US14431		20010504	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 11804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 7 OF 19 USPATFULL on STN
TI Drug screening systems and assays
AB A method of stimulating non-homologous end-joining (NHEJ) of DNA the method comprising performing NHEJ of DNA in the presence of inositol hexakisphosphate (IP.sub.6) or other stimulatory inositol phosphate. An assay of a protein kinase wherein the assay comprises inositol hexakisphosphate (IP.sub.6) or other stimulatory inositol phosphate. The invention also provides screening assays for compounds which may modulate NHEJ and which may be therapeutically useful; and screening assays for compounds which may modulate DNA-PK and related protein kinases and which may be therapeutically useful. Methods of modulating NHEJ and protein kinases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:38591 USPATFULL
TITLE: Drug screening systems and assays
INVENTOR(S): West, Steve Craig, South Mimms Hertfordshire, UNITED KINGDOM
Bartlett-Jones, Michael, London, UNITED KINGDOM
Akemi Hanakahi, Leslyn Ann, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004029130	A1	20040212	
APPLICATION INFO.:	US 2003-296014	A1	20030612	(10)
	WO 2001-GB2180		20010518	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-12179	20000520

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 2260

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 8 OF 19 USPATFULL on STN
TI Methods for detecting dna damage and screening for cancer therapeutics
AB A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:31097 USPATFULL
TITLE: Methods for detecting dna damage and screening for cancer therapeutics
INVENTOR(S): Halazonetis, Thanos, Wynnewood, PA, UNITED STATES
Schultz, Linda B., Suwanee, GA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023235	A1	20040205	
APPLICATION INFO.:	US 2003-276312	A1	20030117	(10)
	WO 2001-US17471		20010530	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-60208716	20000601

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER, BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 9 OF 19 USPATFULL on STN
TI Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
AB Systems and methods for modeling the interactions of the several genes, proteins and other components of a cell, employing mathematical techniques to represent the interrelationships between the cell components and the manipulation of the dynamics of the cell to determine which components of a cell may be targets for interaction with therapeutic agents. A first such method is based on a cell simulation approach in which a cellular biochemical network intrinsic to a phenotype of the cell is simulated by specifying its components and their interrelationships. The various interrelationships are represented with one or more mathematical equations which are solved to simulate a first state of the cell. The simulated network is then perturbed by deleting one or more components, changing the concentration of one or more components, or modifying one or more mathematical equations representing the interrelationships between one or more of the components. The equations representing the perturbed network are solved to simulate a second state of the cell which is compared to the first state to identify the effect of the perturbation on the state of the network, thereby identifying one or more components as targets. A second

method for identifying components of a cell as targets for interaction with therapeutic agents is based upon an analytical approach, in which a stable phenotype of a cell is specified and correlated to the state of the cell and the role of that cellular state to its operation. A cellular biochemical network believed to be intrinsic to that phenotype is then specified by identifying its components and their interrelationships and representing those interrelationships in one or more mathematical equations. The network is then perturbed and the equations representing the perturbed network are solved to determine whether the perturbation is likely to cause the transition of the cell from one phenotype to another, thereby identifying one or more components as targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:306353 USPATFULL			
TITLE:	Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents			
INVENTOR(S):	Hill, Colin, Ithaca, NY, UNITED STATES Khalil, Iya, Ithaca, NY, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003215786	A1	20031120	
APPLICATION INFO.:	US 2002-287173	A1	20021104	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-335999P		20011102	(60)
	US 2002-406764P		20020829	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	KRAMER LEVIN NAFTALIS & FRANKEL LLP, INTELLECTUAL PROPERTY DEPARTMENT, 919 THIRD AVENUE, NEW YORK, NY, 10022			
NUMBER OF CLAIMS:	65			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	62 Drawing Page(s)			
LINE COUNT:	3785			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 10 OF 19 USPATFULL on STN

TI Novel human protein kinases and protein kinase-like enzymes

AB The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:300763 USPATFULL			
TITLE:	Novel human protein kinases and protein kinase-like enzymes			
INVENTOR(S):	Plowman, Gregory D, San Carlos, CA, UNITED STATES Whyte, David, Belmont, CA, UNITED STATES Manning, Gerard, Menlo Park, CA, UNITED STATES Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES Martinez, Ricardo, Foster City, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003211989	A1	20031113	
APPLICATION INFO.:	US 2003-220955	A1	20030226	(10)

WO 2001-US6838 20010302
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 7135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 11 OF 19 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:267307 USPATFULL
TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES
Fox, Edward A., Boston, MA, UNITED STATES
PATENT ASSIGNEE(S): Dana Farber Cancer Institute (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003188326	A1	20031002
APPLICATION INFO.:	US 2002-165099	A1	20020606 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-998027, filed on 2 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245756P	20001103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Page(s)
LINE COUNT: 4045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 12 OF 19 USPATFULL on STN
TI LGALS as modifiers of the CHK pathway and methods of use
AB Human LGALS genes are identified as modulators of the CHK pathway, and thus are therapeutic targets for disorders associated with defective CHK

function. Methods for identifying modulators of CHK, comprising screening for agents that modulate the activity of LGALS are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:237808 USPATFULL			
TITLE:	LGALS as modifiers of the CHK pathway and methods of use			
INVENTOR(S):	Francis-Lang, Helen, San Francisco, CA, UNITED STATES Nicoll, Monique, Pacifica, CA, UNITED STATES Heuer, Timothy S., Pacifica, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003165965	A1	20030904	
APPLICATION INFO.:	US 2003-376133	A1	20030228	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2002-360757P		20020301	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	JAN P. BRUNELLE, EXELIXIS, INC., 170 HARBOR WAY, P.O. BOX 511, SOUTH SAN FRANCISCO, CA, 94083-0511			
NUMBER OF CLAIMS:	25			
EXEMPLARY CLAIM:	1			
LINE COUNT:	2386			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 13 OF 19 USPATFULL on STN

TI Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:237674 USPATFULL			
TITLE:	Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer			
INVENTOR(S):	Lee, John, Somerville, MA, UNITED STATES Thompson, Pamela, Stow, MA, UNITED STATES Lillie, James, Natick, MA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003165831	A1	20030904	
APPLICATION INFO.:	US 2001-814353	A1	20010321	(9)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-191031P		20000321	(60)
	US 2000-207124P		20000525	(60)
	US 2000-211940P		20000615	(60)
	US 2000-216820P		20000707	(60)
	US 2000-220661P		20000725	(60)
	US 2000-257672P		20001221	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109			
NUMBER OF CLAIMS:	66			
EXEMPLARY CLAIM:	1			

LINE COUNT: 4104
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 14 OF 19 USPATFULL on STN
TI Full-length human cDNAs encoding potentially secreted proteins
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:219631 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152921	A1	20030814
APPLICATION INFO.:	US 2001-876997	A1	20010608 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Frank C. Eisenschenk, Ph.D., SALIWANCHIK, LLOYD & SALIWANCHIK, 2421 N.W. 41 STREET, SUITE A-1, GAINESVILLE, FL, 32606-6669
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 27600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 19 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based tests and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:135730 USPATFULL
TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003093819	A1	20030515	
APPLICATION INFO.:	US 2001-998027	A1	20011102	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245756P	20001103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 4421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 19 USPATFULL on STN
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of marker genes are provided, wherein changes in the levels of expression of one or more of the marker genes is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:3444 USPATFULL
TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
INVENTOR(S): Kovats, Steven G., Wilmington, MA, UNITED STATES
Sen, Ami, Framingham, MA, UNITED STATES
Morrissey, Michael P., Brighton, MA, UNITED STATES
Lillie, James, Natick, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceutical, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003003479	A1	20030102	
APPLICATION INFO.:	US 2002-126227	A1	20020419	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-285443P	20010419 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
LINE COUNT: 5284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 19 USPATFULL on STN

TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

AB The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:322455 USPATFULL
TITLE:	Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
INVENTOR(S):	Lillie, James, Natick, MA, UNITED STATES Mills, Gordon, Houston, TX, UNITED STATES Lee, John, Somerville, MA, UNITED STATES
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., Boston, MA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002182619	A1	20021205	
APPLICATION INFO.:	US 2001-35415	A1	20011108	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-246839P	20001108	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109
NUMBER OF CLAIMS:	8
EXEMPLARY CLAIM:	1
LINE COUNT:	6649

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 18 OF 19 USPATFULL on STN

TI Materials and methods relating to the degradation of Cdc25A in response to DNA damage

AB Cdc25A has a role in a further signalling pathway for DNA repair which operates in response to DNA damage, in which Chk1 or Chk2 are activated following DNA damage and phosphorylate Cdc25A at one or more serine residues, and more particularly at Ser123 and/or Ser262 and/or Ser292 and/or Ser504. The phosphorylated Cdc25A is then recognized by the F-box protein and is then degraded in a proteasome dependent manner, thereby allowing the cells to undergo cell cycle arrest and repair. Accordingly, by interfering with the **phosphorylation** and/or degradation of Cdc25A and/or using other strategies to maintain Cdc25A level, this pathway can be used to prevent cells from undergoing repair and thereby increasing the accumulation of DNA damage in the cells, e.g. increasing the fraction of tumor cells which can be killed by DNA damaging therapeutic agents, such as radiation or anti-tumor drugs, or which undergo apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2002:266266 USPATFULL
TITLE:	Materials and methods relating to the degradation of Cdc25A in response to DNA damage
INVENTOR(S):	Mailand, Niels, Kobenhavn, DENMARK Hansen, Jacob Falck, Kobenhavn, DENMARK Bartek, Jiri, Greve, DENMARK Lukas, Jiri, Greve, DENMARK Lukas, Claudia, Greve, DENMARK Syljuasen, Randi, Kobenhavn, DENMARK Lundgren, Karsten, Fredensborg, DENMARK

PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147145	A1	20021010
APPLICATION INFO.:	US 2001-949196	A1	20010907 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-GB1008, filed on 8 Mar 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-5573	20000308
	GB 2001-1021	20010115

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, LLP, P.O. Box 9169, Boston, MA, 02209
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 19 OF 19 USPATFULL on STN
TI Full-length human cDNAs encoding potentially secreted proteins
AB The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:191539 USPATFULL
TITLE: Full-length human cDNAs encoding potentially secreted proteins
INVENTOR(S): Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102604	A1	20020801
APPLICATION INFO.:	US 2000-731872	A1	20001207 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-169629P	19991208 (60)
	US 2000-187470P	20000306 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: John Lucas, Ph.D., J.D., Genset Corporation, 10665 Srrento Valley Road, San Diego, CA, 92121-1609
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 28061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 12 USPATFULL on STN
TI Stress-responsive activator of p300 (strap) protein
AB The invention provides a protein which is a stress-responsive activator of the p300 protein, and nucleic acid sequences encoding the protein. The protein performs a key role in facilitating stress-responsive protein-protein interactions within the p300 co-activator complex. The STRAP protein facilitates the interaction of other proteins in the p300 complex, and is thus a target for assays for modulators of the complex.

ACCESSION NUMBER: 2004:328237 USPATFULL
TITLE: Stress-responsive activator of p300 (strap) protein
INVENTOR(S): La Thangue, Nicholas Barnie, Strathclyde, UNITED KINGDOM
Demonacos, Constantinos, Strathclyde, UNITED KINGDOM
Krstic-Demonacos, Marija, Strathclyde, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004260062	A1	20041223	
APPLICATION INFO.:	US 2004-471573	A1	20040816	(10)
	WO 2002-GB1349		20020319	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-6782	20010319

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 2276

L14 ANSWER 2 OF 12 USPATFULL on STN
TI **P53**-dependent apoptosis-inducing protein and method of screening for apoptosis regulator
AB **p53**-dependent Damage-Inducible Nuclear Protein 1 (p53DINP1 protein) is a **p53**-induced nuclear protein that induces **p53**-dependent apoptosis by regulating **p53** function through Ser 46 **phosphorylation**. A DNA encoding p53DINP1 can be applied as anticancer agents for destroying neoplasms such as tumors, and as therapeutic or preventive agents for diseases associated with **p53**-mediated apoptosis abnormalities. It is also possible to apply the above protein and DNA in methods of screening for candidate compounds for regulating **p53**-mediated apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:320942 USPATFULL
TITLE: **P53**-dependent apoptosis-inducing protein and method of screening for apoptosis regulator
INVENTOR(S): Nakamura, Yusuke, Kanagawa, JAPAN
Arakawa, Hirofumi, Tokyo, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004253595	A1	20041216	
APPLICATION INFO.:	US 2004-484157	A1	20040726	(10)
	WO 2002-JP7305		20020718	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-220349	20010719

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kevin Bastian, Townsend and Townsend and Crew, Two Embarcadero Center, Eighth Floor, San Francisco, CA, 94111-3834
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1897
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 3 OF 12 USPATFULL on STN
TI Modulators of telomere stability
AB The present invention embodies methods of modulating telomere repeat-**binding** factor-2 (TRF2) or cell cycle checkpoint kinase 2 (Chk2) to enhance the survival of a cell. More particularly, the modulators can be used to treat cardiovascular disease by improving the growth and survival of cardiomyocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:307785 USPATFULL
TITLE: Modulators of telomere stability
INVENTOR(S): Schneider, Michael D., Houston, TX, UNITED STATES
Oh, Hidemasa, Houston, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004242461	A1	20041202	
APPLICATION INFO.:	US 2004-820583	A1	20040408	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-461095P	20030408	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI, LLP, 1301 MCKINNEY, SUITE 5100, HOUSTON, TX, 77010-3095
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 4939
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 4 OF 12 USPATFULL on STN
TI Novel SMG-1
AB A novel polypeptide and a novel polynucleotide encoding the same are disclosed.

The polypeptide is SMG-1, a protein included in the phosphatidyl inositol kinase related kinase family, and is useful in constructing a screening system for agents of treating and/or preventing a disease caused by a premature translation termination codon generated by a nonsense mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:178425 USPATFULL
TITLE: Novel SMG-1
INVENTOR(S): Ohno, Shigeo, Tokyo, JAPAN
PATENT ASSIGNEE(S): Japan Science and Technology Agency, Saitama, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004137592	A1	20040715	
APPLICATION INFO.:	US 2003-720460	A1	20031124	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-JP10234, filed on 22 Nov 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-156088	20010524

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HESLIN ROTHENBERG FARLEY & MESITI PC, 5 COLUMBIA CIRCLE, ALBANY, NY, 12203
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 3702
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 5 OF 12 USPATFULL on STN
TI Modulation of checkpoint kinase 1 expression
AB Compounds, compositions and methods are provided for modulating the expression of checkpoint kinase 1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding checkpoint kinase 1. Methods of using these compounds for modulation of checkpoint kinase 1 expression and for diagnosis and treatment of disease associated with expression of checkpoint kinase 1 are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:127462 USPATFULL
TITLE: Modulation of checkpoint kinase 1 expression
INVENTOR(S): Gaarde, William, Carlsbad, CA, UNITED STATES
Freier, Susan M., San Diego, CA, UNITED STATES
Dobie, Kenneth W., Del Mar, CA, UNITED STATES
Watt, Andrew T., Vista, CA, UNITED STATES
PATENT ASSIGNEE(S): Isis Pharmaceuticals Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004097446	A1	20040520	
APPLICATION INFO.:	US 2002-298994	A1	20021116	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE - 46TH FLOOR, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 3681
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 6 OF 12 USPATFULL on STN
TI Drug screening systems and assays
AB A method of stimulating non-homologous end-joining (NHEJ) of DNA the method comprising performing NHEJ of DNA in the presence of inositol hexakisphosphate (IP.sub.6) or other stimulatory inositol phosphate. An assay of a protein kinase wherein the assay comprises inositol hexakisphosphate (IP.sub.6) or other stimulatory inositol phosphate. The invention also provides screening assays for compounds which may modulate NHEJ and which may be therapeutically useful; and screening assays for compounds which may modulate DNA-PK and related protein kinases and which may be therapeutically useful. Methods of modulating NHEJ and protein kinases are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:38591 USPATFULL
TITLE: Drug screening systems and assays
INVENTOR(S): West, Steve Craig, South Mimms Hertfordshire, UNITED

KINGDOM
Bartlett-Jones, Michael, London, UNITED KINGDOM
Akemi Hanakahi, Leslyn Ann, Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004029130	A1	20040212	
APPLICATION INFO.:	US 2003-296014	A1	20030612	(10)
	WO 2001-GB2180		20010518	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-12179	20000520

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 2260
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 7 OF 12 USPATFULL on STN
TI Methods for detecting dna damage and screening for cancer therapeutics
AB A method for detecting DNA damage in a tissue sample involves contacting an immobilized biological sample with a labeled ligand which binds to human 53Bp1, and examining the immobilized sample for the presence of a label generated-detectable signal concentrated in foci in said sample. The presence of concentrated foci is indicative of DNA damage and the presence of diffuse signal is indicative of a normal sample. Diagnostic reagents contain a ligand that binds to human 53Bp1 associated with a detectable label. Diagnostic kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. Compositions that inhibit or antagonize the biological activity of 53Bp1 are identified by suitable assays, and are employed in methods of retarding the growth of a cancer cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2004:31097 USPATFULL
TITLE: Methods for detecting dna damage and screening for cancer therapeutics
INVENTOR(S): Halazonetis, Thanos, Wynnewood, PA, UNITED STATES
Schultz, Linda B., Suwanee, GA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023235	A1	20040205	
APPLICATION INFO.:	US 2003-276312	A1	20030117	(10)
	WO 2001-US17471		20010530	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-60208716	20000601

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HOWSON AND HOWSON, ONE SPRING HOUSE CORPORATION CENTER, BOX 457, 321 NORRISTOWN ROAD, SPRING HOUSE, PA, 19477
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 8 OF 12 USPATFULL on STN

TI Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

AB Systems and methods for modeling the interactions of the several genes, proteins and other components of a cell, employing mathematical techniques to represent the interrelationships between the cell components and the manipulation of the dynamics of the cell to determine which components of a cell may be targets for interaction with therapeutic agents. A first such method is based on a cell simulation approach in which a cellular biochemical network intrinsic to a phenotype of the cell is simulated by specifying its components and their interrelationships. The various interrelationships are represented with one or more mathematical equations which are solved to simulate a first state of the cell. The simulated network is then perturbed by deleting one or more components, changing the concentration of one or more components, or modifying one or more mathematical equations representing the interrelationships between one or more of the components. The equations representing the perturbed network are solved to simulate a second state of the cell which is compared to the first state to identify the effect of the perturbation on the state of the network, thereby identifying one or more components as targets. A second method for identifying components of a cell as targets for interaction with therapeutic agents is based upon an analytical approach, in which a stable phenotype of a cell is specified and correlated to the state of the cell and the role of that cellular state to its operation. A cellular biochemical network believed to be intrinsic to that phenotype is then specified by identifying its components and their interrelationships and representing those interrelationships in one or more mathematical equations. The network is then perturbed and the equations representing the perturbed network are solved to determine whether the perturbation is likely to cause the transition of the cell from one phenotype to another, thereby identifying one or more components as targets.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:306353 USPATFULL

TITLE: Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents

INVENTOR(S): Hill, Colin, Ithaca, NY, UNITED STATES
Khalil, Iya, Ithaca, NY, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003215786	A1	20031120	
APPLICATION INFO.:	US 2002-287173	A1	20021104	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-335999P	20011102	(60)
	US 2002-406764P	20020829	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KRAMER LEVIN NAFTALIS & FRANKEL LLP, INTELLECTUAL PROPERTY DEPARTMENT, 919 THIRD AVENUE, NEW YORK, NY, 10022
NUMBER OF CLAIMS: 65
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 62 Drawing Page(s)
LINE COUNT: 3785

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 9 OF 12 USPATFULL on STN

TI Novel human protein kinases and protein kinase-like enzymes
AB The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:300763 USPATFULL			
TITLE:	Novel human protein kinases and protein kinase-like enzymes			
INVENTOR(S):	Plowman, Gregory D, San Carlos, CA, UNITED STATES Whyte, David, Belmont, CA, UNITED STATES Manning, Gerard, Menlo Park, CA, UNITED STATES Sudarsanam, Sucha, Greenbrae, CA, UNITED STATES Martinez, Ricardo, Foster City, CA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003211989	A1	20031113	
APPLICATION INFO.:	US 2003-220955	A1	20030226	(10)
	WO 2001-US6838		20010302	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007			
NUMBER OF CLAIMS:	28			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	16 Drawing Page(s)			
LINE COUNT:	7135			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 10 OF 12 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2003:267307 USPATFULL			
TITLE:	Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof			
INVENTOR(S):	D'Andrea, Alan D., Winchester, MA, UNITED STATES Taniguchi, Toshiyasu, Boston, MA, UNITED STATES Timmers, Cynthia, Columbus, OH, UNITED STATES Grompe, Markus, Portland, OR, UNITED STATES Fox, Edward A., Boston, MA, UNITED STATES			
PATENT ASSIGNEE(S):	Dana Farber Cancer Institute (U.S. corporation)			
	NUMBER	KIND	DATE	

PATENT INFORMATION: US 2003188326 A1 20031002
APPLICATION INFO.: US 2002-165099 A1 20020606 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-998027, filed on 2 Nov 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245756P	20001103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Page(s)
LINE COUNT: 4045
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 11 OF 12 USPATFULL on STN
TI Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AB Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, mapped on the 3p chromosome, cloned into recombinant vectors, used to prepare recombinant cells and sequenced. The FANCD2 gene sequence provides probes and primers for screening patients in genetic based tests and for diagnosing Fanconi anemia and cancer. It has also been possible to target the FANCD2 gene in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. Vectors are described for use in gene therapy. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the mono-ubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact FA pathway. The FANCD2 has been localized to the nucleus and is associated with BRCA 1 foci.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:135730 USPATFULL
TITLE: Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
INVENTOR(S): D'Andrea, Alan D., Winchester, MA, UNITED STATES
Taniguchi, Toshiyasu, Boston, MA, UNITED STATES
Timmers, Cynthia, Columbus, OH, UNITED STATES
Grompe, Markus, Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003093819	A1	20030515
APPLICATION INFO.:	US 2001-998027	A1	20011102 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-245756P	20001103 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROMBERG & SUNSTEIN LLP, 125 SUMMER STREET, BOSTON, MA, 02110-1618
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)

LINE COUNT: 4421
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L14 ANSWER 12 OF 12 USPATFULL on STN
TI Materials and methods relating to the degradation of Cdc25A in response to DNA damage
AB Cdc25A has a role in a further signalling pathway for DNA repair which operates in response to DNA damage, in which Chk1 or Chk2 are activated following DNA damage and phosphorylate Cdc25A at one or more serine residues, and more particularly at Ser123 and/or Ser262 and/or Ser292 and/or Ser504. The phosphorylated Cdc25A is then recognized by the F-box protein and is then degraded in a proteasome dependent manner, thereby allowing the cells to undergo cell cycle arrest and repair. Accordingly, by interfering with the **phosphorylation** and/or degradation of Cdc25A and/or using other strategies to maintain Cdc25A level, this pathway can be used to prevent cells from undergoing repair and thereby increasing the accumulation of DNA damage in the cells, e.g. increasing the fraction of tumor cells which can be killed by DNA damaging therapeutic agents, such as radiation or anti-tumor drugs, or which undergo apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2002:266266 USPATFULL
TITLE: Materials and methods relating to the degradation of Cdc25A in response to DNA damage
INVENTOR(S): Mailand, Niels, Kobenhavn, DENMARK
Hansen, Jacob Falck, Kobenhavn, DENMARK
Bartek, Jiri, Greve, DENMARK
Lukas, Jiri, Greve, DENMARK
Lukas, Claudia, Greve, DENMARK
Syljuasen, Randi, Kobenhavn, DENMARK
Lundgren, Karsten, Fredensborg, DENMARK
PATENT ASSIGNEE(S): Zealand Pharmaceuticals A/S (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147145	A1	20021010
APPLICATION INFO.:	US 2001-949196	A1	20010907 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-GB1008, filed on 8 Mar 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-5573	20000308
	GB 2001-1021	20010115

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, LLP, P.O. Box 9169, Boston, MA, 02209
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 2668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.